Article
A member of the clinical research team at Florida Cancer Specialists & Research Institute is to be a first author for a breast cancer study to be presented at San Antonio Breast Cancer Symposium.
Fort Myers, Florida — Medical oncologist Manish R. Patel, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), served as the first author of a study examining dose escalation of an oral complete estrogen receptor antagonist/selective ER degrader in cases of advanced and/or metastatic estrogen receptor-positive, HER2-negative breast cancer.
Entitled, “Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer,” the study was shared at the San Antonio Breast Cancer Symposium held Dec. 7-12, 2021.
While still ongoing, the study’s analysis indicates an evolution in the standard of care, to include complete estrogen receptor antagonists.
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.